Please Wait
Applying Filters...
menu
    • menu
    Top first-in-class drug candidates of 2025: Ionis’ donidalorsen, Sanofi’s fitusiran, Cytokinetics’ aficamten await FDA approval

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

    Stock Recap
    #PipelineProspector

    Menu

    Uvamin Retard

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 496Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    24/02/2025 Cambrex Corporation
    U.S.A
    		 CAMBREX PROFARMACO MILANO SRL 4376 TEMAZEPAM 1981-11-12 Active II Complete 2017-10-27 2017-10-16
    24/02/2025 Centaur Pharmaceuticals
    India
    		 CENTAUR PHARMACEUTICALS PVT LTD 25364 TEMAZEPAM USP 2011-10-03 Inactive II N/A